keyword
MENU ▼
Read by QxMD icon Read
search

oral oncology

keyword
https://www.readbyqxmd.com/read/28346240/combined-oral-medroxyprogesterone-levonorgestrel-intrauterine-system-treatment-for-women-with-grade-2-stage-ia-endometrial-cancer
#1
Ji Young Hwang, Da Hee Kim, Hyo Sook Bae, Mi-La Kim, Yong Wook Jung, Bo Seong Yun, Seok Ju Seong, Eunah Shin, Mi Kyoung Kim
OBJECTIVE: The aim of this study was to evaluate the oncologic and pregnancy outcomes of combined oral medroxyprogesterone acetate (MPA)/levonorgestrel-intrauterine system (LNG-IUS) treatment in young women with grade 2-differentiated stage IA endometrial adenocarcinoma who wish to preserve fertility. METHODS: We retrospectively reviewed the medical records of patients with grade 2 stage IA endometrial adenocarcinoma who had received fertility-sparing treatment at CHA Gangnam Medical Center between 2011 and 2015...
March 24, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28344158/laparoscopic-vs-open-approach-for-transverse-colon-cancer-a-systematic-review-and-meta-analysis-of-short-and-long-term-outcomes
#2
REVIEW
Christos Athanasiou, Jonathan Robinson, Marina Yiasemidou, Sonia Lockwood, Georgios A Markides
BACKGROUND: Transverse colon malignancies have been excluded from all randomized controlled trials comparing laparoscopic against open colectomies, potentially due to the advanced laparoscopic skills required for dissecting around the middle colic vessels and the associated morbidity. Concerns have been expressed that the laparospopic approach may compromise the oncological clearance in transverse colon cancer. This study aimed to comprehensively compare the laparoscopic (LPA) to the open (OPA) approach by performing a meta-analysis of long and short term outcomes...
March 24, 2017: International Journal of Surgery
https://www.readbyqxmd.com/read/28339328/mercaptopurine-ingestion-habits-red-cell-thioguanine-nucleotide-levels-and-relapse-risk-in-children-with-acute-lymphoblastic-leukemia-a-report-from-the-children-s-oncology-group-study-aall03n1
#3
Wendy Landier, Lindsey Hageman, Yanjun Chen, Nancy Kornegay, William E Evans, Bruce C Bostrom, Jacqueline Casillas, David S Dickens, Anne L Angiolillo, Glen Lew, Kelly W Maloney, Leo Mascarenhas, A Kim Ritchey, Amanda M Termuhlen, William L Carroll, Mary V Relling, F Lennie Wong, Smita Bhatia
Purpose Children with acute lymphoblastic leukemia (ALL) are generally instructed to take mercaptopurine (6-MP) in the evening and without food or dairy products. This study examines the association between 6-MP ingestion habits and 6-MP adherence, red cell thioguanine nucleotide (TGN) levels, and risk of relapse in children with TMPT wild-type genotype. Methods Participants included 441 children with ALL receiving oral 6-MP for maintenance. Adherence was monitored over 48,086 patient-days using the Medication Event Monitoring System; nonadherence was defined as adherence rate < 95%...
March 24, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28333866/prevention-of-gastrointestinal-side-effects-in-paediatric-oncology-what-are-the-guidelines
#4
Karis K F Cheng
PURPOSE OF REVIEW: Gastrointestinal side-effects, particularly with regard to alimentary tract mucositis and chemotherapy-induced nausea and vomiting (CINV), continue to be frequent and debilitating symptomatic conditions among children and adolescents receiving cytotoxic cancer therapy. Further avenues of progress for mucositis and CINV prevention in paediatric oncology setting are warranted. RECENT FINDINGS: The current article reviews the major guidelines and literature published in 2016 pertaining to the prevention of mucositis and CINV...
March 22, 2017: Current Opinion in Supportive and Palliative Care
https://www.readbyqxmd.com/read/28332989/multicenter-study-of-carbon-ion-radiation-therapy-for-mucosal-melanoma-of-the-head-and-neck-subanalysis-of-the-japan-carbon-ion-radiation-oncology-study-group-j-cros-study-1402-hn
#5
Masashi Koto, Yusuke Demizu, Jun-Ichi Saitoh, Hiroaki Suefuji, Hiroshi Tsuji, Tomoaki Okimoto, Tatsuya Ohno, Yoshiyuki Shioyama, Ryo Takagi, Kenji Nemoto, Takashi Nakano, Tadashi Kamada
PURPOSE: To evaluate the efficacy and safety of carbon-ion radiation therapy (RT) for mucosal melanoma of the head and neck (MMHN) in the Japan Carbon-Ion Radiation Oncology Study Group study. METHODS AND MATERIALS: Patients with MMHN with N0-1M0 status who were treated with carbon-ion RT at 4 institutions in Japan between November 2003 and December 2014 were analyzed retrospectively. Two hundred sixty patients (male, 111; female, 149; median age, 68 years) with histologically proven MMHN were enrolled...
April 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28330568/-evaluation-of-healing-time-of-osteochemonecrosis-of-the-jaw-after-surgery-single-center-retrospective-study-and-review-of-the-literature
#6
A Berquet, A Louvrier, F Denis, F Bornert, E Weber, C Meyer
INTRODUCTION: Osteochemonecrosis of the jaw (ONJ) is a chronic ischemic bone exposure. It has an increasing incidence. ONJ is mainly related to bisphosphonate and denosumab therapies in oncologic settings. Healing is considered uncertain ad as occurring slowly. International recommendations suggest to treat ONJ symptomatically in a first attempt. A surgical procedure, potentially aggressive, should be carefully weight up in patients in poor condition and whose life expectancy is often limited...
February 2017: J Stomatol Oral Maxillofac Surg
https://www.readbyqxmd.com/read/28330462/prospective-phase-ii-trial-of-everolimus-in-pik3ca-amplification-mutation-and-or-pten-loss-patients-with-advanced-solid-tumors-refractory-to-standard-therapy
#7
Seung Tae Kim, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Won Ki Kang, Ho Yeong Lim
BACKGROUND: We designed a single-arm, open-label phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy (#NCT02449538). METHODS: Everolimus was administered orally at a daily dose of 10 mg continuously (28-day cycles). Treatment was continued until progression of the disease or intolerable toxicity was observed. Based on Simon's two-stage optimal design, 10 patients were treated with everolimus during the first stage...
March 23, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28327898/adherence-to-capecitabine-in-preoperative-treatment-of-stage-ii-and-iii-rectal-cancer-do-we-need-to-worry
#8
R Font, J A Espinas, L Layos, M Martinez Villacampa, J Capdevila, M Tobeña, A Pisa, C Pericay, C Lezcano, E Fort, I Cardona, N Berga, J Solà, J M Borras
Background: : Preoperative oral capecitabine plus radiotherapy has been progressively adopted in oncology units to provide more convenient care to patients with rectal cancer, but little is known about adherence to this therapy. Patients and methods: : Prospective, multicentre observational study in six hospitals in metropolitan Barcelona (Spain), in patients with stage II and III rectal cancer. Assessment of adherence was based on the medical report in the clinical history, a patient questionnaire and a pill count in the pharmacy service upon finalization of treatment...
March 6, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28324180/lateral-pharyngotomy-approach-in-the-treatment-of-oropharyngeal-carcinoma
#9
Andy Bertolin, Guido Ghirardo, Marco Lionello, Luciano Giacomelli, Marco Lucioni, Giuseppe Rizzotto
Surgery for early-intermediate oropharyngeal squamous cell carcinoma (OPSCC) may involve using transoral endoscopic approaches or open surgical procedures. "Lateral pharyngotomy" (LP) is an open surgical approach that improves exposure of the oropharyngeal region, while avoiding mandibulotomy. The aim of the present study was to retrospectively analyze our experience with the surgical treatment of early-intermediate OPSCC using the LP approach, and to investigate the potentially prognostic clinical and/or pathological factors that might identify patients at higher risk of recurrence after primary surgery...
March 21, 2017: European Archives of Oto-rhino-laryngology
https://www.readbyqxmd.com/read/28315543/metastatic-colorectal-cancer-management-with-trifluridine-tipiracil%C3%A2
#10
Teresa White, Heidi Larson, Alexandra Minnella, Howard S Hochster
BACKGROUND: Treatment-related adverse events (AEs) are common in patients with metastatic colorectal cancer (mCRC) receiving chemotherapy. These AEs may affect patient adherence, particularly with completely oral regimens, such as trifluridine/tipiracil (TAS-102, Lonsurf®), an antimetabolite agent for patients with mCRC refractory or intolerant to standard therapies.
. OBJECTIVES: This article reviews strategies for promoting adherence and educating patients and caregivers about oral therapy with trifluridine/tipiracil...
April 1, 2017: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/28315532/oral-chemotherapy-adherence-a-novel-nursing-intervention-using-an-electronic-health-record-workflow%C3%A2
#11
German Rodriguez, Minerva A Utate, George Joseph, Thelma St Victor
In the ambulatory care setting, chemotherapy regimens have become increasingly complex with the combination of induction treatments and oral medications. Nurses at one cancer center implemented an oral adherence tracking documentation system in the electronic health record (EHR). Oncology nurses assessed and monitored adherence to oral chemotherapy at each clinical encounter and during telephone calls and then documented findings in the EHR. After implementing this new standardized approach, adherence rates were captured as a metric for the organization...
April 1, 2017: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/28314699/safety-and-tolerability-of-idelalisib-lenalidomide-and-rituximab-in-relapsed-and-refractory-lymphoma-the-alliance-for-clinical-trials-in-oncology-a051201-and-a051202-phase-1-trials
#12
Sonali M Smith, Brandelyn N Pitcher, Sin-Ho Jung, Nancy L Bartlett, Nina Wagner-Johnston, Steven I Park, Kristy L Richards, Amanda F Cashen, Anthony Jaslowski, Scott E Smith, Bruce D Cheson, Eric Hsi, John P Leonard
BACKGROUND: A new generation of biological and targeted agents might potentially replace traditional cytotoxic agents in lymphoma. Lenalidomide plus rituximab was felt to be a safe and promising backbone based on available data. Idelalisib is an oral phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor that has promising activity as a monotherapy in refractory indolent lymphomas. The primary objective of these two trials was to determine the maximum tolerated dose of lenalidomide in combination with rituximab and idelalisib in relapsed follicular and mantle cell lymphoma...
March 14, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28297339/deformable-image-registration-and-interobserver-variation-in-contour-propagation-for-radiation-therapy-planning
#13
Adam C Riegel, Jeffrey G Antone, Honglai Zhang, Prachi Jain, Jagdeep Raince, Anthony Rea, Angelo M Bergamo, Ajay Kapur, Louis Potters
Deformable image registration (DIR) and interobserver variation inevitably introduce uncertainty into the treatment planning process. The purpose of the current work was to measure deformable image registration (DIR) errors and interobserver variability for regions of interest (ROIs) in the head and neck and pelvic regions. Measured uncertainties were combined to examine planning margin adequacy for contours propagated for adaptive therapy and to assess the trade-off of DIR and interobserver uncertainty in atlas-based automatic segmentation...
May 2016: Journal of Applied Clinical Medical Physics
https://www.readbyqxmd.com/read/28286660/preference-of-elderly-patients-to-oral-or-intravenous-chemotherapy-in-heavily-pre-treated-recurrent-ovarian-cancer-final-results-of-a-prospective-multicenter-trial
#14
Radoslav Chekerov, Philipp Harter, Stefan Fuxius, Lars Christian Hanker, Linn Woelber, Lothar Müller, Peter Klare, Wolfgang Abenhardt, Yoana Nedkova, Isil Yalcinkaya, Georg Heinrich, Harald Sommer, Sven Mahner, Pauline Wimberger, Dominique Koensgen-Mustea, Rolf Richter, Gülten Oskay-Oezcelik, Jalid Sehouli
BACKGROUND: Palliative systemic treatment in elderly gynaecological cancer patients remains a major challenge. In recurrent ovarian cancer (ROC), treosulfan an active alkylating drug showed similar cytotoxicity whether as oral (p.o.) or intravenous (i.v.) application. The aim of this innovative trial was to evaluate the preference of elderly patients (≥65 years) for p.o. or i.v. chemotherapy focusing compliance, outcome, toxicities, and geriatric aspects as secondary endpoints. METHODS: Patients with ROC had the free choice between treosulfan i...
2017: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/28282956/effects%C3%A2-of%C3%A2-resveratrol%C3%A2-supplementation%C3%A2-on%C3%A2-methotrexate%C3%A2-chemotherapy-induced%C3%A2-bone%C3%A2-loss
#15
Alice M C Lee, Tetyana Shandala, Pei Pei Soo, Yu-Wen Su, Tristan J King, Ke-Ming Chen, Peter R Howe, Cory J Xian
Intensive cancer chemotherapy is known to cause bone defects, which currently lack treatments. This study investigated the effects of polyphenol resveratrol (RES) in preventing bone defects in rats caused by methotrexate (MTX), a commonly used antimetabolite in childhood oncology. Young rats received five daily MTX injections at 0.75 mg/kg/day. RES was orally gavaged daily for seven days prior to, and during, five-day MTX administration. MTX reduced growth plate thickness, primary spongiosa height, trabecular bone volume, increased marrow adipocyte density, and increased mRNA expression of the osteogenic, adipogenic, and osteoclastogenic factors in the tibial bone...
March 9, 2017: Nutrients
https://www.readbyqxmd.com/read/28282274/improving-the-management-of-patients-with-low-risk-neutropenic-fever-at-the-cleveland-clinic-taussig-cancer-institute
#16
Lindsey Martin Goodman, Bassam Estfan, Alberto Montero, Girish Kunapareddy, Jessica Lau, Erika Gallagher, Carolyn Best, Barb Tripp, Machelle Moeller, Brian Bolwell, James Stevenson
PURPOSE: Neutropenic fever (NF) is an oncologic emergency and has resulted historically in inpatient management. The Multinational Association for Supportive Care in Cancer (MASCC) score can be used to identify patients with NF at a low risk of complications who can be managed safely as outpatients. Despite established guidelines supporting outpatient management of low-risk neutropenic fever (LRNF), provider awareness is low, and inpatient admission for intravenous antibiotics continues to be standard of care...
March 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28280302/defective-dna-repair-mechanisms-in-prostate-cancer-impact-of-olaparib
#17
REVIEW
Francesca De Felice, Vincenzo Tombolini, Francesco Marampon, Angela Musella, Claudia Marchetti
The field of prostate oncology has continued to change dramatically. It has truly become a field that is intensely linked to molecular genetic alterations, especially DNA-repair defects. Germline breast cancer 1 gene (BRCA1) and breast cancer 2 gene (BRCA2) mutations are implicated in the highest risk of prostate cancer (PC) predisposition and aggressiveness. Poly adenosine diphosphate ribose polymerase (PARP) proteins play a key role in DNA repair mechanisms and represent a valid target for new therapies. Olaparib is an oral PARP inhibitor that blocks DNA repair pathway and coupled with BRCA mutated-disease results in tumor cell death...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28260629/uplc-esi-ms-ms-study-of-the-effect-of-green-tea-extract-on-the-oral-bioavailability-of-erlotinib-and-lapatinib-in-rats-potential-risk-of-pharmacokinetic-interaction
#18
Hadir M Maher, Nourah Z Alzoman, Shereen M Shehata, Ashwag O Abahussain
Green tea (GT) is one of the most consumed beverages worldwide. Tyrosine kinase inhibitors (TKIs) belong to the oral targeted therapy that gained much interest in oncology practice, among which are erlotinib (ERL) and lapatinib (LAP). Since green tea polyphenols (GTP) are known to be inhibitors of receptor tyrosine kinases, GTE could likely potentiate the anticancer effect of TKIs, but with a possibility of pharmacokinetic (PK) interaction with co-administered TKIs. In this study, the effect of GTE on the PK of ERL/LAP in rats was studied...
April 1, 2017: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
https://www.readbyqxmd.com/read/28259610/vandetanib-plus-gemcitabine-versus-placebo-plus-gemcitabine-in-locally-advanced-or-metastatic-pancreatic-carcinoma-vip-a-prospective-randomised-double-blind-multicentre-phase-2-trial
#19
Gary Middleton, Daniel H Palmer, William Greenhalf, Paula Ghaneh, Richard Jackson, Trevor Cox, Anthony Evans, Victoria E Shaw, Jonathan Wadsley, Juan W Valle, David Propper, Harpreet Wasan, Stephen Falk, David Cunningham, Fareeda Coxon, Paul Ross, Srinivasan Madhusudan, Nick Wadd, Pippa Corrie, Tamas Hickish, Eithne Costello, Fiona Campbell, Charlotte Rawcliffe, John P Neoptolemos
BACKGROUND: Erlotinib is an EGFR tyrosine kinase inhibitor that has shown a significant but only marginally improved median overall survival when combined with gemcitabine in patients with locally advanced and metastatic pancreatic cancer. Vandetanib is a novel tyrosine kinase inhibitor of VEGFR2, RET, and EGFR, all of which are in involved in the pathogenesis of pancreatic cancer. We investigated the clinical efficacy of vandetanib when used in combination with gemcitabine in patients with advanced pancreatic cancer...
March 1, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28258343/efficacy-safety-and-feasibility-of-antifungal-prophylaxis-with-posaconazole-tablet-in-paediatric-patients-after-haematopoietic-stem-cell-transplantation
#20
Michaela Döring, Karin Melanie Cabanillas Stanchi, Manon Queudeville, Judith Feucht, Franziska Blaeschke, Patrick Schlegel, Tobias Feuchtinger, Peter Lang, Ingo Müller, Rupert Handgretinger, Werner J Heinz
PURPOSE: Paediatric recipients of haematopoietic stem cell transplantation (HSCT) have a high risk for invasive fungal infections. Posaconazole oral suspension has proven to be effective in antifungal prophylaxis in adult and paediatric patients. A new posaconazole tablet formulation with absorption independent of the gastric conditions was approved by the FDA in 2013. This is the first report on the use of posaconazole tablets in paediatric patients. METHODS: This single-centre study included 63 paediatric patients with haemato-oncological malignancies who received posaconazole for antifungal prophylaxis after HSCT...
March 3, 2017: Journal of Cancer Research and Clinical Oncology
keyword
keyword
91223
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"